

Stochastic individual based models with application to modelling of cancer therapy

Anton Bovier, Anna Kraut,

Martina Baar, Loren Coquille, Florian Kreten, Hannah Mayer,
Nicole Glodde, Meri Rogova, Michael Hölzel, Thomas Tütting,
Kai Echelmeyer, Martin Rumpf



Institute for Applied Mathematics Bonn

CIRM, 29.06.2018

hausdorff center for mathematics



Adaptive dynamics

Adaptive dynamics is a biological theory that describes the evolution of biological populations:

Adaptive dynamics

Adaptive dynamics is a biological theory that describes the evolution of biological populations:

- in space of phenotypes and/or geographic locations
- with locally varying fitness
- interacting through ecological competition
- subject to mutation/migration

Adaptive dynamics should explain how an initial populations distributes and diversifies to create a structured population. Key mechanisms are

Adaptive dynamics

Adaptive dynamics is a biological theory that describes the evolution of biological populations:

- in space of phenotypes and/or geographic locations
- with locally varying fitness
- interacting through ecological competition
- subject to mutation/migration

Adaptive dynamics should explain how an initial populations distributes and diversifies to create a structured population. Key mechanisms are

- drift towards higher fitness (canonical equation)
- evolutionary branching (splitting of populations to reduce competition)

The standard model

Markov processes on space of positive measures.

The standard model

Markov processes on space of positive measures.

- Trait-space: \mathcal{X} some Polish space (e.g. $\mathbb{R}^d, \mathbb{Z}^d$);

The standard model

Markov processes on space of positive measures.

- Trait-space: \mathcal{X} some Polish space (e.g. $\mathbb{R}^d, \mathbb{Z}^d$);
- Configuration space: Point measures on \mathcal{X} : $\nu_t \equiv \sum_{i=1}^{N_t} \delta_{x_i(t)}$ represents a population of N_t individuals, i , with traits $x_i(t)$.

The standard model

Markov processes on space of positive measures.

- Trait-space: \mathcal{X} some Polish space (e.g. $\mathbb{R}^d, \mathbb{Z}^d$);
- Configuration space: Point measures on \mathcal{X} : $\nu_t \equiv \sum_{i=1}^{N_t} \delta_{x_i(t)}$ represents a population of N_t individuals, i , with traits $x_i(t)$.
- Generator acting on functions $f : \mathcal{M}_p(\mathcal{X}) \rightarrow \mathbb{R}$ by

$$\begin{aligned} Lf(\nu) &= \int_{\mathcal{X}} [f(\nu + \delta_x) - f(\nu)] b(x)(1 - m(x))\nu(dx) \\ &+ \int_{\mathcal{X}} [f(\nu - \delta_x) - f(\nu)] \left[d(x) + \int_{\mathcal{X}} c(x, y)\nu(dy) \right] \nu(dx) \\ &+ \int_{\mathcal{X}} \int_{\mathcal{X}} [f(\nu + \delta_{x+y}) - f(\nu)] m(x)M(x, dy)\nu(dx). \end{aligned}$$

The standard model

Here the functions d, b, c, p, m have the following meaning:

The standard model

Here the functions d, b, c, p, m have the following meaning:

- $b(x)$: the natural birth rate of an individual with trait x ;

The standard model

Here the functions d, b, c, p, m have the following meaning:

- $b(x)$: the natural birth rate of an individual with trait x ;
- $d(x)$: the natural death rate of individual with trait x ;

The standard model

Here the functions d, b, c, p, m have the following meaning:

- $b(x)$: the natural **birth rate** of an individual with trait x ;
- $d(x)$: the natural **death rate** of individual with trait x ;
- $c(x, y)$ the increment of the death rate of an individual with trait x due to the presence of an individual with trait y (**competition kernel**);

The standard model

Here the functions d, b, c, p, m have the following meaning:

- $b(x)$: the natural **birth rate** of an individual with trait x ;
- $d(x)$: the natural **death rate** of individual with trait x ;
- $c(x, y)$ the increment of the death rate of an individual with trait x due to the presence of an individual with trait y (**competition kernel**);
- $m(x)$: rate of **mutation** of an individual x when giving birth;

The standard model

Here the functions d, b, c, p, m have the following meaning:

- $b(x)$: the natural **birth rate** of an individual with trait x ;
- $d(x)$: the natural **death rate** of individual with trait x ;
- $c(x, y)$ the increment of the death rate of an individual with trait x due to the presence of an individual with trait y (**competition kernel**);
- $m(x)$: rate of **mutation** of an individual x when giving birth;
- $M(x, dy)$: **probability distribution** of the type of a **mutant** child of an individual of type x .

Application to modelling of cancer evolution and therapy


Can these models be applied to cancer and its treatment?

This would require :

- Identification of the key mechanisms and players effecting the evolution of a tumour under treatment
- Quantitative identification of parameters
- Efficient numerical simulation of the model

Immunotherapy of melanoma


Over the last years, we have tried to do all this for specific immunotherapies of melanoma in a mice model that was implemented at Bonn University Hospital. Starting point were experiments by Landsberg et al. where the following scenario was observed:



A first model

New feature to be included in the model:



- genetically identical individuals can express different phenotypes
- phenotypes switch randomly within lifecycle ("bet hedging")
- switch rates can be changed by the presence of other "individuals" ("phenotypic plasticity")



A first model



New feature to be included in the model:

- genetically identical individuals can express different phenotypes
- phenotypes switch randomly within lifecycle ("bet hedging")
- switch rates can be changed by the presence of other "individuals" ("phenotypic plasticity")



Comparison of experimental data

obtained by Landsberg et al. with simulations for biologically reasonable parameters



Left: Blue and red curves show therapy with and without reactivation of T-cells.


Right: Blue curves correspond to simulations where the T-cell population becomes extinct (can be seen as therapy without reactivation) and red curves to survival of T-cells (can be seen as therapy with reactivation).

Combination treatment



- Glodde studied **evolution of melanomas** under adoptive cell transfer therapy (ACT) combined with MET-inhibitor INC280
- **Therapy protocol:** HCrnel12 melanoma cells are transplanted into the mouse and left to grow
 - ▶ after 16 days (tumour size 3-4mm diam) cytotoxic T-cells are injected
 - ▶ for the first five days (16-21) **METi** is injected twice daily

Combination treatment

- Glodde studied **evolution of melanomas** under adoptive cell transfer therapy (ACT) combined with MET-inhibitor INC280
- **Therapy protocol:** HClmel12 melanoma cells are transplanted into the mouse and left to grow
 - ▶ after 16 days (tumour size 3-4mm diam) cytotoxic T-cells are injected
 - ▶ for the first five days (16-21) **METi** is injected twice daily





First try



Problem: Therapy appears more effective for large tumours contrary to experiments!

First try




Problem: Therapy appears more effective for large tumours contrary to experiments!

Solution:

- Include the effect of T-cell exhaustion to slow down immune response
- Include spatial structure of the tumour

Exhaustion and spatial structure




The full generator



$$\begin{aligned}
 (\mathcal{L}\phi)(\nu_t) &= (\phi(\nu_t + \delta_{Di}) - \phi(\nu_t)) (1 - m)b_{Di}\nu_t(Di) \\
 &\quad + (\phi(\nu_t - \delta_{Di} + \delta_{Dead}) - \phi(\nu_t)) (d_{Di} + c_{Di,Di}\nu_t(Di) + c_{Di,De}\nu_t(De) + c_{Di,KO}\nu_t(KO))\nu_t(Di) \\
 &\quad + (\phi(\nu_t + \delta_{De} - \delta_{Di}) - \phi(\nu_t)) (s_{Di,De} + s_{Di,De}^{Cy}\nu_t(Cy))\nu_t(Di) \\
 &\quad + (\phi(\nu_t + \delta_{De}) - \phi(\nu_t)) (1 - m)b_{De}\nu_t(De) \\
 &\quad + (\phi(\nu_t - \delta_{De} + \delta_{Dead}) - \phi(\nu_t)) (d_{De} + c_{De,Di}\nu_t(Di) + c_{De,De}\nu_t(De) + c_{De,KO}\nu_t(KO))\nu_t(De) \\
 &\quad + (\phi(\nu_t + \delta_{Di} - \delta_{De}) - \phi(\nu_t)) s_{De,Di}\nu_t(De) \\
 &\quad + (\phi(\nu_t + \delta_{KO}) - \phi(\nu_t)) (b_{KO}\nu_t(KO) + mb_{Di}\nu_t(Di) + mb_{De}\nu_t(De)) \\
 &\quad + (\phi(\nu_t - \delta_{KO} + \delta_{Dead}) - \phi(\nu_t)) (d_{KO} + c_{KO,Di}\nu_t(Di) + c_{KO,De}\nu_t(De) + c_{KO,KO}\nu_t(KO))\nu_t(KO) \\
 &\quad + (\phi(\nu_t - \delta_{Dead}) - \phi(\nu_t)) d_{Dead}\nu_t(Dead) \\
 &\quad + (\phi(\nu_t + \delta_{CD} + 3\delta_{Cy}) - \phi(\nu_t)) b_{CD}\nu_t(Di)\nu_t(CD)(1 - h\nu_t(Cy))_+ \left(\frac{\nu_t(Di)}{\nu_t(Tot)} \right)^\alpha \\
 &\quad + (\phi(\nu_t - \delta_{Di} + \delta_{Dead}) - \phi(\nu_t)) t_{Di}\nu_t(Di)\nu_t(CD)(1 - h\nu_t(Cy))_+ \left(\frac{\nu_t(Di)}{\nu_t(Tot)} \right)^\alpha \\
 &\quad + (\phi(\nu_t - \delta_{CD}) - \phi(\nu_t)) d_{CD}\nu_t(CD) \\
 &\quad + (\phi(\nu_t - \delta_{Cy}) - \phi(\nu_t)) d_{Cy}\nu_t(Cy)
 \end{aligned}$$

Results including T-cell exhaustion, spatial structure

Results including T-cell exhaustion, spatial structure





Results including T-cell exhaustion, spatial structure



Late relapse

- Stochastic effects play a role even in large populations




KO mutants



Glodde et al engineered several melanoma variants that do not express the gp100-antigen and are resistant to T-cell treatment.

KO mutants





Glodde et al engineered several melanoma variants that do not express the gp100-antigen and are resistant to T-cell treatment.




KO mutants





KO mutants



KO mutants





KO simulations



- Without treatment the knockout is suppressed by the wildtype
- Under therapy the knockout prevails
 - ▶ No competitive pressure when the wildtype is in remission

KO mutants, natural mutations



Conclusion

- Experimental data can be described by the probabilistic/deterministic model
- New key aspects have been identified: T-cell exhaustion, spatial structure
- Random fluctuations determine the success of therapy
- Phenotypic switch and genetic selection as mechanism to escape therapy

Thank you for your attention!



Baar M, Coquille L, Mayer H, Hölzel M, Rogava M, Tüting T and Bovier A.
A stochastic individual-based model for immunotherapy of cancer.
Scientific Reports 6, 24169 (2016)



Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M and Tüting T.
Melanomas resist t-cell therapy through inflammation-induced reversible dedifferentiation. *Nature* 490:412–416 (2012)



Glodde, N.
c-MET inhibition improves T-cell immunotherapy of mouse melanomas but cannot prevent outgrowth of genetic antigen loss variants.
Ph.D. Thesis, Bonn Univ. 2016



Glodde, N.,, Hölzel, M.
Reactive neutrophil responses dependent on the receptor Tyrosine Kinase c-Met limit cancer immunotherapy.
Immunity 47:1–14 (2017)



Hölzel M, Bovier A, Tüting T.
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? *Nat Rev Cancer* 13:365–376 (2013)